Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals Revenue by Segment

Period Ending	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Research and Development	586.74M	603.82M	407.74M	412.20M	517.20M	519.24M	476.54M	479.40M
Research and Development Growth	13.44%	16.29%	-14.44%	-14.02%	69.35%	56.10%	71.59%	68.45%
Commercial	380.92M	340.66M	309.94M	293.36M	286.36M	294.71M	300.57M	308.75M
Commercial Growth	33.02%	15.59%	3.12%	-4.98%	-7.55%	-1.13%	0.74%	1.94%

Revenue by Product

Period Ending	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Spinraza	222.35M	223.56M	225.96M	216.41M	214.41M	224.45M	228.72M	240.51M
Spinraza Growth	3.70%	-0.40%	-1.21%	-10.02%	-12.67%	-6.44%	-4.11%	-0.65%
Wainua	42.79M	35.16M	28.52M	20.28M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tegsedi and Waylivra	35.25M	36.17M	30.83M	33.74M	34.74M	34.11M	36.57M	34.42M
Tegsedi and Waylivra Growth	1.44%	6.05%	-15.69%	-1.96%	7.17%	13.49%	22.78%	16.81%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.